drugset / Trial / NCT05009719
Risk-adapted Donor Lymphocyte Infusion After Allo-HSCT in Children With Hematologic Malignancy
Non-randomizedParallel-groupOpen-labelPrevention
Summary
Allo-hsct is potentially curative method of treatment for children and adolescent with hematologic malignancy. However, relapses of disease after allo-hsct occur up to 50% of patients and constitute the main cause of mortality after HSCT. Donor lymphocytes infusion (DLI) is a form of immunotherapy based on developement of reaction "graft versus from leukemia". This study evaluates the safety and efficacy of risk-adapted srtategy of DLI for prophylaxis and prevention posttransplant relapses in children and adolescent with hematologic malignancy.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2023-04-01
- Completion
- 2024-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | donor lymphocytes | Cell therapy | 100000 cells/kg | Intravenous |
| Subject | donor lymphocytes | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | donor lymphocytes | Cell therapy | 1e+08 cells/kg | Intravenous |